Acasti Pharma, Inc. - (ACST): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACST Stock Price Chart Interactive Chart >
ACST Price/Volume Stats
| Current price | $0.46 | 52-week high | $1.35 |
| Prev. close | $0.44 | 52-week low | $0.34 |
| Day low | $0.43 | Volume | 174,200 |
| Day high | $0.47 | Avg. volume | 121,710 |
| 50-day MA | $0.57 | Dividend yield | N/A |
| 200-day MA | $0.65 | Market Cap | 20.52M |
Acasti Pharma, Inc. - (ACST) Company Bio
Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.
Latest ACST News From Around the Web
Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayThe biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning! |
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangeAcasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it has applied and received approval for a voluntary delisting of its common shares from the TSX Venture Exchange ("TSXV"). The delisting from the TSXV will not affect the Company's listing on the NASDAQ Capital Market (the "NASDAQ"). The common shares will continue to trade on |
Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceAcasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D'alvise, CEO, will present and host one-on-one meetings with investors at the Oppenheimer 33rd Annual Healthcare Conference, held virtually and taking place on March 13-15, 2023. |
We're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Acasti Pharma Recognizes Rare Disease DayAcasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, recognizes and celebrates Rare Disease Day (February 28), as established by the European Organization for Rare Diseases. |
ACST Price Returns
| 1-mo | -9.93% |
| 3-mo | -8.18% |
| 6-mo | -21.17% |
| 1-year | -62.30% |
| 3-year | -84.85% |
| 5-year | -94.36% |
| YTD | -8.18% |
| 2022 | -60.24% |
| 2021 | -51.54% |
| 2020 | -86.73% |
| 2019 | 195.18% |
| 2018 | -11.70% |
Loading social stream, please wait...